Breaking News

PAREXEL Acquires ATLAS

July 2, 2014

Expands footprint in Turkey, the Middle East, and North Africa

PAREXEL has acquired ATLAS Medical Services, a provider of clinical research services in Turkey, the Middle East, and North Africa. ATLAS provides services for all phases of clinical development, along with study planning and feasibility, site selection, data management, and medical writing, and has therapeutic expertise in oncology, hematology, endocrinology, cardiovascular, anesthesiology, infectious diseases and the central nervous system. The firm also provides regulatory services to support product registration.
 
ATLAS, headquartered in Istanbul, has 35 employees, with additional offices in Ankara and Izmir. Its 2013 revenues were approximately $4 million.
 
Josef von Rickenbach, chairman and chief executive officer of PAREXEL said, "The acquisition of ATLAS strengthens PAREXEL's presence in Turkey, the Middle East and North Africa. These markets are of increasing importance to our clients who are looking for market access and a broad spectrum of patient populations for clinical trials. In addition, ATLAS has been a trusted business partner to PAREXEL for many years, and their infrastructure and staff are already aligned with our processes and operations. By fully integrating ATLAS into PAREXEL's global operations, we will enhance our ability to help clients more quickly achieve their goals of bringing important therapies to patients not only in Turkey, the Middle East, and North Africa, but also throughout the rest of the world."
 

blog comments powered by Disqus
  • 16th Annual $alary $urvey

    16th Annual $alary $urvey

    Tim Wright, Editor||June 3, 2015
    Welcome to Contract Pharma’s Sixteenth Annual Salary Survey! This year’s results are derived from more than 500 respondents f

  • Newsmakers: PCI

    Newsmakers: PCI

    Tim Wright, Editor||June 2, 2015
    PCI execs talk about the recent opening of the company’s new North American clinical facility, as well as other trends in the market

  • How Sterilization of Primary Packaging Influences the Results of E&L Studies

    How Sterilization of Primary Packaging Influences the Results of E&L Studies

    Thorsten Sogding, Daniel Canton, Daniel Haines, Uwe Rothhaar, SCHOTT Pharma Services ||June 2, 2015
    As the demands that are being placed on the quality and stability of medications continue to increase, the interactions that take place between the primary packaging container and filled drug product are becoming increasingly important